- 1.Male or female, 18 years of age or over, 2.Patient with hypertension and at least
three other CV risk factors, 3.Hypertension, treated or not, but not at the currently
recommended goals (140/90 mmHg for most patients, 130/80 mmHg for patients with
diabetes or nephropathy). In case of treated hypertension, patients should be on their
current treatment for at least 4 weeks before randomisation,
- 1. Patient with a history of coronary heart disease, 2.Patients with a history of
familial hypercholesterolemia, 3.Patient with malignant HTN, 4.Non-essential
hypertension, 5.Known hypersensitivity to dihydropyridines, 6.Patients already
receiving a dihydropyridine, 7.Known hypersensitivity to HMG-CoA-reductase inhibitors,
8.Patients currently receiving or who has received a HMG-CoA-reductase within the 3
months prior to selection, 9.Patients currently receiving or who has received a fibric
acid, resins, ezetimibe, nicotinic acid and all other drug which is known to affect
lipid levels, within 6 weeks prior to selection,